Cagatay, T. Et Al. 2018. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk. CLINICAL RESPIRATORY JOURNAL , vol.12, no.4 , 1668-1675.

Cagatay, T., Bingol, Z., Kiyan, E., Yegin, Z., Okumus, G., Arseven, O., ... Erkan, F.(2018). Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk. CLINICAL RESPIRATORY JOURNAL , vol.12, no.4, 1668-1675.

Cagatay, Tülin Et Al. "Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk," CLINICAL RESPIRATORY JOURNAL , vol.12, no.4, 1668-1675, 2018

Cagatay, Tülin Et Al. "Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk." CLINICAL RESPIRATORY JOURNAL , vol.12, no.4, pp.1668-1675, 2018

Cagatay, T. Et Al. (2018) . "Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk." CLINICAL RESPIRATORY JOURNAL , vol.12, no.4, pp.1668-1675.

@article{article, author={Tülin ÇAĞATAY Et Al. }, title={Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk}, journal={CLINICAL RESPIRATORY JOURNAL}, year=2018, pages={1668-1675} }